An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer

Silvia von Karstedt1,2,3 and Henning Walczak2,4,5

Abstract
Twenty-one percent of all human cancers bear constitutively activating mutations in the proto-oncogene KRAS. This incidence is substantially higher in some of the most inherently therapy-resistant cancers including 30% of non-small cell lung cancers (NSCLC), 50% of colorectal cancers, and 95% of pancreatic ductal adenocarcinomas (PDAC). Importantly, survival of patients with KRAS-mutated PDAC and NSCLC has not significantly improved since the 1970s highlighting an urgent need to re-examine how oncogenic KRAS influences cell death signaling outputs. Interestingly, cancers expressing oncogenic KRAS manage to escape antitumor immunity via upregulation of programmed cell death 1 ligand 1 (PD-L1). Recently, the development of next-generation KRASG12C-selective inhibitors has shown therapeutic efficacy by triggering antitumor immunity. Yet, clinical trials testing immune checkpoint blockade in KRAS-mutated cancers have yielded disappointing results suggesting other, additional means endow these tumors with the capacity to escape immune recognition. Intriguingly, oncogenic KRAS reprograms cell death pathways triggered by death receptors of the tumor necrosis factor (TNF) receptor superfamily. Perverting the course of their intended function, KRAS-mutated cancers use endogenous TNF-related apoptosis-inducing ligand (TRAIL) and its receptor(s) to promote tumor growth and metastases. Yet, endogenous TRAIL–TRAIL-receptor signaling can be therapeutically targeted and, excitingly, this may not only counteract oncogenic KRAS-driven cancer cell migration, invasion, and metastasis, but also the immunosuppressive reprogramming of the tumor microenvironment it causes. Here, we provide a concise summary of the current literature on oncogenic KRAS-mediated reprogramming of cell death signaling and antitumor immunity with the aim to open novel perspectives on combinatorial treatment strategies involving death receptor targeting.

Facts

- KRAS is the most frequently mutated proto-oncogene in human cancers.
- KRAS-mutated cancers show poor checkpoint blockade response.
- TNF superfamily ligand signaling is re-programmed to mediate migration, invasion, and metastasis in KRAS-mutated cancer.

Open questions

- Can antagonistic targeting of TNF superfamily ligand signaling impact KRAS-driven cancer?
- How does targeting of TNF superfamily ligand signaling influence the tumor immune environment?
- Could targeting of TNF superfamily ligand signaling serve as an alternative immunotherapeutic approach for KRAS-mutated cancers?

KRAS-mutated cancers: cancers with unmet needs
Survival rates for most KRAS-mutated cancers such as non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) have not significantly improved since the 1970s. This dire situation is, in part,
caused by the fact that KRAS-mutant cancers including PDAC are commonly only diagnosed at an advanced stage due to the absence of early symptoms. Whereas many KRAS effector pathways have been targeted using small molecule inhibitors against kinases activated downstream of KRAS\(^1\), their clinical application has raised concern over toxicity and even paradoxical effects promoting the disease through transactivation of wild-type (WT) v-raf murine sarcoma viral oncogene homolog B1(BRAF)\(^2\). Other potentially KRAS-mutant-selective therapeutic targets have emerged from synthetic lethality screens comparing effects on KRAS-mutated vs. KRAS WT cell lines\(^3\)–\(^7\). However, the fact that activating point mutations uniquely occur in tumor cells has fueled efforts to develop small molecule inhibitors designed to selectively target these point mutant variants. As such, inhibitors that selectively bind and inactivate KRAS\(^{G12C}\)\(^8\),\(^9\) have been developed showing promising results in first human trials\(^10\). Whilst hopes are high that this may provide a silver bullet against KRAS\(^{G12C}\)-mutated cancers, the fate of inhibitors of oncogenic BRAF\(^{V600E}\) has taught us to be careful with such hopes. Most importantly, however, cancers driven by all other forms of point-mutated KRAS including KRAS\(^{G12D}\), the most prevalent KRAS point mutation across all human cancers\(^11\), remain difficult to treat. Apart from these drug discovery-driven approaches, cell biological research has unearthed several important concepts highlighting mechanisms of how oncogenic KRAS manipulates antitumor immunity and physiological cell death signaling. These two concepts, which turn out to be a lot more closely interlinked at the level of immune cell–tumor cell encounters than previously thought, will be discussed in this review.

**Patients with KRAS-mutated PDAC do not benefit from immune checkpoint blockade**

Undeniably, the second decade of the third millennium has been the decade in which the inhibition of so-called immune checkpoints which serve to prevent autoimmunity\(^12\) has come of age in cancer therapy. The two immune checkpoint receptor–ligand systems whose inhibition has proven to be successful in the cancer clinic are the cytotoxic T lymphocyte-associated protein 4 (CTLA4)–B7-1/B7-2\(^{13}\) and the programmed cell death protein-1 (PD-1)–programmed cell death 1 ligand 1 (PD-L1) systems\(^14\). Indeed, immune checkpoint blockade (ICB) has become a gamechanger in the therapy of certain cancers, especially advanced melanoma, with unprecedented response rates\(^15\)–\(^18\). Interestingly, expression of oncogenic RAS has been shown to upregulate PD-L1 via stabilization of its mRNA\(^19\), suggesting this as a possible means by which KRAS-mutated cancers may escape immunosurveillance. However, in PDAC, ICB so far failed to provide clinical benefit\(^20\)–\(^22\) (summarized in Table 1, Table 1 Selection of published and ongoing clinical trials testing immune checkpoint blockade (ICB) in pancreatic cancer.

| Trial identifier | Cancer types | Treatment groups | Response |
|-----------------|--------------|-----------------|----------|
| Completed       | PDAC, NSCLC, Melanoma, CRC, renal cancer | BMS-936559 (anti-PD-L1) | 0% (PDAC) |
| Completed       | PDAC, NSCLC, melanoma | Ipilimumab | 0% 1 delayed PR |
| Completed       | PDAC, NSCLC, melanoma | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + PDR0100 (PD-1/2, anti-CTLA-4) | 0% 3 (D/T), PR |
| NCT02777700     | Advanced/malignant PDAC | Durvalumab (anti-PD-L1) vs. Durvalumab + Pembrolizumab (PD-L1) | pending |
| NCT02777700     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + PDR0100 | pending |
| NCT02777700     | Advanced/malignant PDAC | Nivolumab (anti-PD-1) vs. Nivolumab + BMS-188832 (PD-L1) | pending |
| NCT03843592     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + PDR0100 | pending |
| NCT03843592     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + Defactinib (PI3K inhibitor) | pending |
| NCT03797580     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + Defactinib (PI3K inhibitor) | pending |
| NCT03797580     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + Defactinib (PI3K inhibitor) | pending |
| NCT03797580     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + Defactinib (PI3K inhibitor) | pending |
| NCT03797580     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + Defactinib (PI3K inhibitor) | pending |
| NCT03797580     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + Defactinib (PI3K inhibitor) | pending |
| NCT03797580     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + Defactinib (PI3K inhibitor) | pending |
| NCT03797580     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + Defactinib (PI3K inhibitor) | pending |
| NCT03797580     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + Defactinib (PI3K inhibitor) | pending |
| NCT03797580     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + Defactinib (PI3K inhibitor) | pending |
| NCT03797580     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + Defactinib (PI3K inhibitor) | pending |
| NCT03797580     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + Defactinib (PI3K inhibitor) | pending |
| NCT03797580     | Advanced/malignant PDAC | Pembrolizumab (anti-PD-1) vs. Pembrolizumab + Defactinib (PI3K inhibitor) | pending |
also reviewed in \(^{23,24}\). This may, in part, be caused by the fact that cancers require a high tumor mutational burden (TMB) to achieve therapeutic efficacy via checkpoint blockade\(^{25,26}\). PDAC, the cancer with the highest incidence of KRAS mutations, however, does not present with very high TMB\(^{27}\). In addition, tumors that initially respond to ICB due to high TMB may acquire resistance by inactivation of the IFN-\(\gamma\) pathway\(^{28,29}\). Intriguingly, however, an inhibitor which selectively targets oncogenic KRAS\(^{G12C}\), AMG510 was recently found to enable effective antitumor immunity\(^{10}\). Interestingly, this immune response was sufficient to also attack KRAS\(^{G12D}\)-expressing tumors in trans demonstrating that antitumor immunity is prevented by oncogenic KRAS, but can be reinstated through its inhibition. Together with the fact that PDAC patients poorly respond to ICB, these results imply that an alternative mechanism functionally similar to, but molecularly distinct from, conventional immune checkpoints is responsible for oncogenic KRAS-driven reprogramming of the tumor immune microenvironment (TIME) and, consequently, for immune evasion of KRAS-mutated cancers. Another possibility is that, besides conventional immune checkpoints, this currently elusive immune checkpoint provides an additional layer of protection preventing recognition and destruction by the immune system.

The TNF superfamily member TRAIL and its receptors

Tumor necrosis factor is the founding member of the TNF superfamily (TNF-SF) of cytokines. Members of the TNF-SF are synthesized as type II transmembrane proteins. They are frequently expressed by activated immune cells but can also be cleaved from their surface and can then act as soluble cytokines\(^{30}\). Tumors are constitutively exposed to the functional consequences of signaling induced by various members of the TNF-SF, produced by diverse immune cells in the TIME, as part of the immune cell-mediated antitumor attack. Members of the TNF-SF bind to specific receptors that form part of a corresponding protein family, the TNFR-SF. Members of this family are characterized by the presence of up to six repeats of a characteristic cysteine-rich domain within their extracellular portion. Six members of the TNFR-SF contain a so-called intracellular death domain (DD), which is required for cell death induction. These receptors are therefore also referred to as death receptors. The most intensively studied receptors of this type are TNF-receptor 1 (TNF-R1), CD95 (Fas/APO-1), and the two TRAIL death receptors, TRAIL-receptor 1 and 2 (TRAIL-R1 and TRAIL-R2)\(^{31}\).

Within this protein family, TRAIL\(^{32}\) received a high level of interest due to its capacity to selectively kill tumor cells, importantly without killing any essential normal cell type\(^{33,34}\). TRAIL has been shown to bind five different cellular receptors, which can be subdivided into the ones that contain a DD, TRAIL-R1 (DR4), and TRAIL-R2 (DR5), and those that do not, TRAIL-R3, TRAIL-R4, and osteoprotegerin (OPG) (reviewed in \(^{35–37}\)). OPG is a soluble regulatory receptor for RANKL but has been shown to also bind TRAIL. Mice only express one DD-containing receptor for TRAIL (mTRAIL-R/MK) which is equally homologous to human TRAIL-R1 and TRAIL-R2. Moreover, two additional mouse receptors, mDcTRAIL-R1 and mDcTRAIL-R2, have been described which lack an intracellular DD. All of the alternative human and murine TRAIL-Rs have been suggested to function as ligand “decoys”, competing for TRAIL binding to the cell death-inducing receptors, a theoretical concept which has been rather difficult to validate under non-overexpression conditions. Recently, the membrane-proximal domain (MPD) within human TRAIL-R2, an amino acid sequence which is shared with mTRAIL-R, was identified to be required for Rac1 activation and migration in KRAS-driven cancers\(^{38}\). Of note, the MPD of TRAIL-R2 shares a lower degree of conservation with that of TRAIL-R1 than with the MPD of CD95, a death receptor which has been shown to activate Rac1 in neurons\(^{39}\).

TRAIL-induced signaling pathways: a brief recapitulation of the corner stones

**FADD/Caspase 8-dependent apoptotic TRAIL signaling**

Upon binding of TRAIL, TRAIL-R1 and TRAIL-R2 form homotrimeric, possibly also heterotrimeric receptor–ligand complexes that are assembled into large, higher-order complexes\(^{40,41}\). Receptor oligomerization allows for the recruitment of Fas-associated protein with a death domain (FADD) via its DD to the DD of TRAIL-R1 and/or TRAIL-R2. Making use of its death-effector domain (DED), FADD recruits the initiator caspases 8 and 10 via their respective DEDs. The resulting complex is referred to as the death-inducing signaling complex (DISC)\(^{42–44}\). Upon activation and cleavage, active caspases 8 and 10 are released from the DISC allowing for the cleavage of cytosolic substrates including effector caspases such as caspase 3. Finally, effector caspases cleave inhibitor of caspase-activated DNAse (iCAD) leading to the activation of caspase-activated DNase (CAD), which is responsible for the hallmark DNA fragmentation observed during apoptosis\(^{45}\). In so-called type I cells, DISC formation is sufficient to induce extrinsic apoptosis in target cells. Yet in type II cells, DISC formation alone is insufficient for full activation of effector caspases due to the inhibitory effect exerted by the X-linked inhibitor of apoptosis protein (XIAP)\(^{46}\). However, caspase 8 also cleaves Bid. Truncated Bid aids Bax- and Bak-mediated mitochondrial outer membrane permeabilization (MOMP)\(^{47}\). MOMP leads to the release of Smac/DIABLO into the cytosol, which antagonizes XIAP. In type II but not in type I cells, this part
of the pathway is required for cell death induction, providing a molecular explanation for the type I–type II cell dichotomy. Another consequence of MOMP is the release of cytochrome C from mitochondria which, together with Apaf1 and the initiator caspase 9, forms the apoptosome, a multimeric caspase-activatory complex which is also capable of activating effector caspases—essentially serving as an “intracellular DISC”.

**RIPK1/RIPK3-dependent necroptotic TRAIL signaling**

Apoptotic DISC components have been shown to actively suppress aberrant induction of necroptosis, a type of regulated or programmed necrosis. This was first proven genetically by showing that embryonic lethality of deficiency in caspase 8 or FADD could be reversed by co-ablation of receptor-interacting serine/threonine-protein kinase 3 (RIPK3) or RIPK1. Therefore, unlike apoptosis, necroptosis is not mediated but suppressed by caspase activity. Instead, necroptosis is executed by the kinase activity of RIPK1 and RIPK3. Whilst most studies on necroptosis have been in the context of TNF stimulation, CD95L and TRAIL can be necroptotic under certain conditions. Interestingly, the linear ubiquitin chain assembly complex (LUBAC) forms part of both, the TRAIL-R1/2-associated complex I and the cytoplasmic complex II of TRAIL signaling, limiting TRAIL-induced apoptosis and necroptosis.

**RIPK1-dependent pro-tumor TRAIL signaling**

Signaling via TRAIL-R1, TRAIL-R2 and TRAIL-R4 can induce activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a master regulator of the immune response. In the context of TRAIL stimulation, NF-κB promotes migration and invasion. Interestingly, RIPK1 presence in the native TRAIL DISC was shown to augment NF-κB activation when caspases are inhibited. Moreover, TRAIL-induced NF-κB activation is increased by FADD presence, caspase inhibition, and LUBAC activity. Apart from a role for RIPK1 in the DISC as an activator of NF-κB, the formation of a secondary intracellular signaling complex has been proposed to activate NF-κB, mitogen-activated protein kinases (MAPKs), JNK, and p38 pathways. In vitro, TRAIL can trigger migration in a RIPK1-, Schmidt-Ruppin A-2 viral oncogene homolog (Src)- and Signal transducer and activator of transcription 3 (STAT3)-dependent manner. Lastly, RIPK1 has been reported to be required for TRAIL-induced NF-κB activation, survival, and proliferation.

**Oncogenic KRAS-mediated rewiring of TRAIL signaling**

Activating point mutations in the small GTPase KRAS lead to its constitutive activation. Thereby, cancers with KRAS mutations experience constitutively elevated signaling via KRAS effector pathways such as activation of the phosphatidylinositol 3 kinase (PI3) kinase pathway via direct interaction of KRAS with the catalytic PI3K subunit p110α. Interestingly, p110α overexpression in melanocytes can protect cells from TRAIL-induced apoptosis. Moreover, small molecule inhibition of PI3K was shown to sensitize to TRAIL-induced apoptosis through elevating Bid expression. Yet, studies using small molecules inhibitors for PI3K without further target validation have to be taken with a note of caution as the kinase inhibitor PIK-75, thought to act through inhibition of p110α, sensitizes cancer cells to TRAIL-induced apoptosis by inhibiting CDK9, whereas specific inhibitors of p110α failed to exert this effect. Another major effector pathway activated by oncogenic KRAS is the MAPK-family member extracellular regulated kinase (ERK), which can also be activated by TRAIL.
Importantly, inactivation of ERK signaling as a consequence of cellular detachment can sensitize cancer cells to TRAIL-induced apoptosis\textsuperscript{67}. Given these and other studies, it was expected that KRAS-mutated cells would be more resistant to TRAIL-induced apoptosis. Yet, it came as a surprise when oncogenic KRAS was found to not only render colorectal cancer cells resistant to TRAIL and CD95L, but to convert the respective ligand-induced signals into migration-activating ones\textsuperscript{68}. Moreover, treatment with exogenous TRAIL promoted KRAS-mutated PDAC metastases\textsuperscript{69}. Whilst these studies highlighted KRAS mutations as contraindication for TRAIL-R agonistic treatments, the function and reasons for high endogenous expression of TRAIL and TRAIL-Rs observed in these cancers remained unknown. Intriguingly, however, these findings proposed an intriguing hypothesis: cancers might profit from highly expressing TRAIL and TRAIL-Rs. Indeed, this hypothesis proved to be correct as endogenous tumor cell-expressed mTRAIL-R promoted KRAS-driven NSCLC and PDAC growth and metastasis by activating the small GTPase Rac1 in vivo\textsuperscript{38}. Moreover, Rho-associated protein kinase (ROCK) inhibition by oncogenic KRAS was sufficient to enable endogenous TRAIL-R2-mediated migration also in KRAS wild-type cells\textsuperscript{38} (concept summarized in Fig. 1). The latter observation implies that this previously unrecognized mechanism may be more widely utilized, also in oncogenic contexts beyond cancer with mutated KRAS. Of note, c-Raf which can function as a KRAS effector upstream of ERK was shown to suppress ROCK, thereby regulating CD95-mediated cell death\textsuperscript{70}.

![Fig. 2 TRAIL expression is a superior marker of overall survival in PDAC. a, c The TCGA PDAC dataset (PAAD) was analyzed for overall survival split by median expression of PD-L1 (CD274, a) or TRAIL (TNFSF10, c). b, d Data as in a, c were analyzed for disease free survival. Kaplan-Meier survival plots are shown. The GEPIA analysis tool was used (http://gepia.cancer-pku.cn).](image-url)
Hence, inhibition of the interactions of endogenous TRAIL–TRAIL-R2 and/or CD95L–CD95 may prove a viable therapeutic concept in oncogene-activated cancers with ROCK inhibition.

**Immune-modulatory activities of TRAIL–TRAIL-R interaction: an immune checkpoint for KRAS-mutated cancer?**

The therapeutic effect of inhibition of TRAIL or CD95L may, however, extend beyond the reach of blocking their role in tumor biology. In this context, it appears particularly noteworthy that mice deficient for TRAIL-R71 or TRAIL are more susceptible to induction of autoimmune diabetes and arthritis suggesting a function for the TRAIL–TRAIL-R system in preventing autoimmunity. In line with this concept, TRAIL expression on T cells was shown to induce tolerance upon encounter with potentially immunogenic antigens in order to prevent aberrant immune responses. Moreover, TRAIL upregulation on CD4+ Foxp3+ regulatory T cells (Tregs) was responsible for the elimination of T effector cells in a skin graft model and, thereby, for suppression of anti-graft immunity. In addition, co-activation of TRAIL-Rs and the T-cell receptor has been shown to suppress T-cell activation.

Intriguingly, many biological effects observed for endogenous TRAIL–TRAIL-R signaling are reminiscent of the effects observed for immune checkpoints preventing autoimmune disease. In a similar manner to the PD-1–PD-L1 system, expression of TRAIL and its receptors is frequently upregulated in cancer. Interestingly, in PDAC, a cancer in which conventional ICB failed to provide clinical benefit, high PD-L1 expression only correlates with shortened progression-free but not overall survival. Importantly, in the same PDAC patient cohort, high TRAIL expression does not correlate with progression-free but with shortened overall survival, suggesting that the inhibition of TRAIL may provide therapeutic benefit for PDAC patients. Endogenous TRAIL-R2 was shown to promote KRAS-driven cancer through cancer cell-autonomous Rac1 activation and non-cancer-cell-autonomous reprogramming of the TIME into one conducive of type 2 macrophage accumulation. Thus, blocking the TRAIL–TRAIL-R2 interaction may be beneficial for patients with KRAS-mutated cancers by acting on three levels: (i) by blocking cell-autonomous Rac1 activation; (ii) through inhibiting the creation of a type 2 macrophage-conducive TIME; and (iii) by prolonging CD8 T-cell activation, allowing for an increased level of “auto-reactive” immunity functionally similar to, but, importantly, molecularly distinct from, conventional ICB (concepts summarized in Fig. 3).

**Conclusions**

Although the discovery of conventional ICB has revolutionized the therapy of several cancers, unfortunately PDAC, the cancer with the highest incidence of KRAS mutations, does not form part of this group. Reasons for this may partly lie in poor immunogenicity and poor perfusion. Yet, KRAS-mutated cancers often highly express TRAIL and TRAIL-Rs. Whereas KRAS-mutated tumors appear to drive immune evasion via alternative means, in addition to manipulating PD-L1 expression. Interestingly, KRAS-mutated cancers often highly express TRAIL and TRAIL-Rs. Whereas KRAS-mutated tumors are more resistant to induction of apoptosis by ectopically added TRAIL, they engage the endogenous TRAIL–TRAIL-R system in disease progression. In addition, the survival of activated CD8 T cells is regulated via TRAIL–TRAIL-R. We conclude that inhibiting endogenous TRAIL in KRAS-mutated cancers may not only inhibit tumor growth, invasion, and metastasis, but also enhance adaptive immunity against these cancers. In
keeping with the irony of PD-1, being originally named for its supposed function as an inducer of programmed death, the bona fide TRAIL—TRAIL-R and CD95L—CD95 death receptor–ligand systems may turn out to serve as alternative, possibly additional immune checkpoint systems whose inhibition may prove essential to extend the ICβ concept beyond the conventional ICβs, importantly, also to KRAS-mutated cancer.

This review is dedicated to the memory of the wonderful human being, our friend Yool Hoog, who always appreciated a "school of provocative thought" in science. S.v.K. is funded by a Max-Eder-Junior Research Group grant (701235509) by the German Cancer Aid, by the German Research Foundation (DFG) in the context of a project grant (432038712), SFB 1399 and SFB 1403, an eMed consortium grant (01ZX1901A) funded by the German state (BMBF) and a project grant (A06) funded by the center for molecular medicine (CMMC), Cologne, Germany. H.W. is supported by an Alexander von Humboldt Professorship Award, a Wellcome Trust Investigator Award (214342/Z/18/Z), a Cancer Research UK (CRUK) programme grant (A06323), a Medical Research Council UK Grant (MR/S00811X/1) and the German Research Foundation (DFG) in the context of SFB 1399 and SFB 1403.

Author details
1Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany.
2CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
3Center for Molecular Medicine Cologne, Medical Faculty, University Hospital of Cologne, Cologne, Germany.
4Institute for Biochemistry I, Medical Faculty, University of Cologne, Cologne, Germany.
5Centre for Cell Death, Cancer, and Inflammation (CCCI), UCL Cancer Institute, University College, London WC1E 6BT, UK

Conflict of interest
S.v.K. and H.W. are named inventors on one (S.v.K.) and two (H.W.) patent applications, respectively, covering some of the therapeutic concepts discussed here. H. W. is founder and shareholder of Apogenix AG, a biopharmaceutical company which develops a biotherapeutic inhibitor of CD95L.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 22 January 2020 Revised: 28 February 2020 Accepted: 3 March 2020
Published online: 17 March 2020

References
1. Downward, J. Targeting RAS and PI3K in lung cancer. Nat. Med. 14, 1315–1316 (2008).
2. Poulikos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427–430 (2010).
3. Singh, A. & Settleman, J. Oncogenic KRas ‘addiction’ and synthetic lethality. Cell Cycle 8, 2656–2657 (2009).
4. Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 855–848 (2009).
5. Barbae, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108–112 (2009).
6. Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642–655 (2012).
7. Dietlein, F. et al. A synergistic interaction between Chk1 and MK2 inhibitors in KRAS-mutant. Cancer Cell 162, 146–159 (2015).
8. Ostrem, J. M., Peters, U., Sos, M. S., Wells, J. A. & Shokat, K. M. K-RasG12C inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).
9. Patricelli, M. P. et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6, 316–329 (2016).
10. Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217–223 (2019).
11. Hobbis, G. A., Der, C. J. & Rossman, K. L. RAIs isoforms and mutations in cancer at a glance. J. Cell Sci. 129, 1287–1292 (2016).
12. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
13. Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
14. Probst, H. C., McCoy, K., Okazaki, T., Honja, T. & van den Broek, M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6, 280–286 (2005).
15. Ho:l, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
16. Margolin, K. et al. Ipilimumab plus ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459–465 (2012).
17. Ribas, A. et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31, 616–622 (2013).
18. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
19. Coelho, M. A. et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity 47, 1083–1099.e6 (2017).
20. O’reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1431 (2019).
21. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).
22. Royal, R. E. et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33, 828–833 (2010).
23. Johnson, B. A., Yarchoan, M., Lee, V., Laheru, D. A. & Jaffee, E. M. Strategies for increasing pancreatic tumor immunogenicity. Clin. Cancer Res. 23, 1656–1669 (2017).
24. Hendriksen, A., Dyh-Pollak, A., Chen, I. & Nielsen, D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat. Rev. 78, 17–30 (2019).
25. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
26. Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
27. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
28. Gao, J. et al. Loss of IFNγ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397–406.e9 (2016).
29. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in Melanoma. N. Engl. J. Med. 375, 819–829 (2016).
30. Aggarwal, B. B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3, 745–756 (2003).
31. Locksley, R. M., Killeen, N. & Lenardo, M. J. The TNF family that induces apoptosis in the immune system. Cell 3, 673–682 (1995).
32. Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5, 157–163 (1999).
33. Ashkenazi, A. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155–162 (1999).
34. Kantetrudt, von,S., Montinaro, A. & Walczak, H. Exploring the TRAILS less travelled: TRAIL in cancer biology and therapy. Nat. Rev. 17, 352–366 (2017).
35. Lemke, J., Kantetrudt, von,S., Zinggibe, J. B. & Walczak, H. Getting TRAIL back on track for cancer therapy. Cell Death Differ. 21, 1350–1364 (2014).
36. Ashkenazi, A. Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. J. Clin. Invest. 125, 487–489 (2015).
37. Kantetrudt, von,S. et al. Cancer cell-autonomous TRAIL signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell 27, 561–573 (2015).

Official journal of the Cell Death Differentiation Association
39. Ruan, W., Lee, C. T. & Deitsbarat. A novel juxtamembrane domain in tumor necrosis factor receptor superfamily molecules activates Ract and controls neurite growth. Mol. Biol. Cell 19, 3192–3202 (2008).

40. Valley, C. C. et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized. J. Biol. Chem. 287, 21265–21278 (2012).

41. Graves, J. D. et al. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell 26, 177–189 (2014).

42. Kischkel, F. C. et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611–620 (2000).

43. Kischkel, F. C. et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 276, 46639–46646 (2001).

44. Sprick, M. R. et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors and DNA degradation during apoptosis. Nature 391, 96–99 (1998).

45. Jost, P. J. et al. XAP discriminates between type I and type II FAS-induced apoptosis. Nature 460, 1035–1039 (2009).

46. Schug, J. T., Gonzalez, F., Houlscooper, R. H., Vaz, F. M. & Gottlieb, E. Bid is cleaved by caspase-8 within a native complex on the mitochondrial membrane. Cell Death Differ. 18, 538–548 (2011).

47. Pan, G., O’Rourke, K. & Dixit, V. M. Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J. Biol. Chem. 273, 5841–5846 (1998).

48. Paspasakis, M. & Vandenabeele, P. Necroptosis and its role in inflammation. Nature 517, 311–320 (2015).

49. Kaiser, W. J. et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471, 368–372 (2011).

50. Obrant, A. et al. Catalytic activity of the caspase-8-FPLU complex inhibits RIP3-dependent necrosis. Nature 471, 363–367 (2011).

51. Dillen, C. P. et al. RIP1 blocks early postnatal lethality mediated by caspase-8 and RIP3. Cell 157, 1189–1202 (2014).

52. Zhang, H. et al. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 471, 373–376 (2011).

53. Declercq, W., Vanden Berghe, T. & Vandenabeele, P. RIP kinases at the crossroads of cell death and survival. Cell 138, 229–232 (2009).

54. Varfolomeev, E. et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 280, 40599–40608 (2005).

55. Laforêt, E. et al. The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death. EMBO J. 36, 1147–1166 (2017).

56. Ishimura, N., Isomoto, H., Bronk, S. F. & Gores, G. J. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G129–G136 (2006).

57. Harper, N., Farow, S. N., Kaptein, A., Cohen, G. M. & MacFarlane, M. Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-kappa B activation by inhibition of apical caspases. J. Biol. Chem. 276, 34743–34752 (2001).

58. Hartwig, T. et al. The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCRI. Mol. Cell 65, 730–742 e5 (2017).

59. Azizi, K. et al. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Stat3-dependent invasion in resistant non-small cell lung cancer cells. J. Cell Sci. 125, 4651–4661 (2012).

60. Lin, Y. et al. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol. Cell Biol. 20, 6638–6645 (2000).

61. Gupta, S. et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129, 957–968 (2007).

62. Fisk, M. et al. P3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ. 11, 1084–1091 (2004).

63. Goez-Brinchen-Khader, N., Lane, D., Matte, L., Rancourt, C. & Piché, A. The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene 29, 5523–5536 (2010).

64. Okuneva, Y. et al. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ. 21, 491–502 (2014).

65. Belyaevskaya, L. L. et al. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer 60, 335–365 (2008).

66. Grosse-Wilde, A. et al. TRAIL-R deficiency in mice enhances lymph-node metastasis without affecting primary tumor development. J. Clin. Invest. 118, 100–110 (2008).

67. Hoogwater, F. J. H. et al. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 138, 2357–2367 (2010).

68. Trauzol, A. et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25, 7434–7439 (2006).

69. Pazzolla, D., Meissl, K., Kucienova, L., Rubiolo, C. & Baccarini, M. Raf-1 sets the threshold of Fas sensitivity by modulating Rok-alpha signaling. J. Cell Biol. 171, 1013–1022 (2005).

70. Finnberg, N., Klein-Szanto, A. J. P. & El-Deiry, W. S. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorgenesis. J. Clin. Invest. 118, 111–123 (2008).

71. Lammahmed-Cherradi, S.-E., Zheng, S., Tisch, R. M. & Chen, Y. H. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 52, 2274–2278 (2003).

72. Morel, J., Audo, R., Hahne, M. & Combe, B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem. 280, 15709–15718 (2005).

73. Lammahmed-Cherradi, S.-E., Zheng, S.-J., Maguschak, K. A., Peschon, J. & Chen, Y. H. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice. Nat. Immunol. 4, 255–260 (2003).

74. Ren, X. et al. Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4+CD25+ regulatory T cells. Cell Death Differ. 14, 2076–2084 (2007).

75. Lehnet, C. et al. TRAIL-receptor costimulation inhibits proximal TCR signaling and suppresses human T cell activation and proliferation. J. Immunol. 193, 4021–4031 (2014).

76. Ganten, T. M. et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J. Mol. Med. 87, 995–1007 (2009).

77. Macher-Goeppinger, S. et al. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin. Cancer Res. 15, 650–659 (2009).

78. Heilman, T. et al. Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients. J. Mol. Med. 97, 1155–1167 (2019).